UNITED STATES **SECURITIES AND EXCHANGE COMMISSION** Washington, D.C. 20549 **SCHEDULE 13D**

(Amendment No. 3)*

BridgeBio Pharma, Inc.
(Name of Issuer)
Common Stock, par value \$0.001 per share
(Title of Class of Securities)
10806X102
(CUSIP Number)
Andrew Genser
General Counsel
600 Washington Boulevard, Floor 11
Stamford, Connecticut 06901
(212) 672-7050
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
August 16, 2024
(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box:
Note : Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1	NAMES	NAMES OF REPORTING PERSONS							
1	Viking (Viking Global Investors LP							
	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP								
2	Z								
	SEC US	E ONLY							
3									
	SOURC	E OF FU	UNDS (SEE INSTRUCTIONS)						
4	OO - oth	OO - other							
_	CHECK	K BOX II	F DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)						
5									
	CITIZE	NSHIP (OR PLACE OF ORGANIZATION						
6	Delawar	re							
		_	SOLE VOTING POWER						
		7	0 (see Item 5)						
		•	SHARED VOTING POWER						
NUMBER OF SE BENEFICIA	LLY	Y	25,120,991 (see Item 5)						
OWNED BY F		0	SOLE DISPOSITIVE POWER						
WITH		9	0 (see Item 5)						
		10	SHARED DISPOSITIVE POWER						
		10	25,120,991 (see Item 5)						
11	AGGRI	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON							
11	25,120,991 (see Item 5)								
		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)							
12	INSTRU	CHON	3)						
	DEDCE	NT OF (CLASS REPRESENTED BY AMOUNT IN ROW (11)						
13		see Item							
		,							
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)								

^{1.} All share percentage calculations in this Amendment No. 3 to the Schedule 13D are based on 188,032,738 shares of Common Stock, par value \$0.001 per share, of BridgeBio Pharma, Inc. (the "<u>Issuer</u>") outstanding as of July 25, 2024, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission (the "<u>Commission</u>") on August 1, 2024.

				-				
	NAMES OF REPORTING PERSONS							
1	Viking (Global Pe	erformance LLC					
_	CHECK	X THE A	APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗆				
2								
	SEC US	SE ONLY	Y					
3								
4	SOURC	CE OF F	UNDS (SEE INSTRUCTIONS)					
4	OO - otl	ner						
_	CHECH	K BOX I	F DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)					
5								
_	CITIZE	ENSHIP	OR PLACE OF ORGANIZATION					
6	Delawai	re						
	ı	_	SOLE VOTING POWER					
		7	0 (see Item 5)					
	SHARED VOTING POWER		SHARED VOTING POWER					
NUMBER OF S BENEFICIA	LLY	8	631,167 (see Item 5)					
OWNED BY		9	SOLE DISPOSITIVE POWER					
WITH	WITH		WIIH		0 (see Item 5)			
		10	SHARED DISPOSITIVE POWER					
		10	631,167 (see Item 5)					
11	AGGRI	EGATE .	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON					
11	631,167 (see Item 5)							
			F THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE					
12	mork	INSTRUCTIONS)						
	PERCE	NT OF	CLASS REPRESENTED BY AMOUNT IN ROW (11)					
13		ee Item 5						
			ORTING PERSON (SEE INSTRUCTIONS)					
14		JE KEPU	ORTING FERSON (SEE INSTRUCTIONS)					
	00	00						

			-					
4	NAMES OF REPORTING PERSONS							
1	Viking (Viking Global Equities Master Ltd.						
	СНЕСЬ	THE A	APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) [
2		(a) = (b) E						
	SEC US	SE ONLY	Y					
3								
4	SOURC	E OF F	UNDS (SEE INSTRUCTIONS)					
4	OO - oth	ner						
-	CHECK	K BOX I	F DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)					
5								
	CITIZE	NSHIP	OR PLACE OF ORGANIZATION					
6	Cayman	Islands						
		_	SOLE VOTING POWER					
		7	0 (see Item 5)					
			SHARED VOTING POWER					
NUMBER OF S BENEFICIA	ALLY	8	631,167 (see Item 5)					
OWNED BY REPORTING I	PERSON	0	SOLE DISPOSITIVE POWER					
WITH		9	0 (see Item 5)					
		10	SHARED DISPOSITIVE POWER					
		10	631,167 (see Item 5)					
44	AGGRI	EGATE .	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON					
11	631,167	(see Iten	n 5)					
		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)						
12	INSTRU	OCTION						
	DEDCE	NT OF	CLASS DEDDESENTED DV AMOUNT IN DOW (11)					
13			CLASS REPRESENTED BY AMOUNT IN ROW (11)					
	0.3% (se							
14)F REPO	ORTING PERSON (SEE INSTRUCTIONS)					
17	CO	CO						

70011 110. 1000	01110 2		001122 022 102	1 450 0 01 1					
	NAMES	S OF RE	EPORTING PERSONS						
1	Viking I	Viking Long Fund GP LLC							
	CHECK	THE A	APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) [
2		(a) \square							
3	SEC US	SEC USE ONLY							
3									
4	SOURC	E OF F	UNDS (SEE INSTRUCTIONS)						
4	OO - oth	ner							
5	СНЕСЬ	K BOX I	F DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2	(E) [
3									
(CITIZE	NSHIP	OR PLACE OF ORGANIZATION						
6	Delawar	Delaware							
		_	SOLE VOTING POWER						
		7	0 (see Item 5)						
			SHARED VOTING POWER						
NUMBER OF BENEFICE	ALLY	8	251,204 (see Item 5)						
OWNED BY REPORTING	PERSON	0	SOLE DISPOSITIVE POWER						
WITH		9	0 (see Item 5)						
		10	SHARED DISPOSITIVE POWER						
		10	251,204 (see Item 5)						
11	AGGRI	EGATE .	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON						
11	251,204 (see Item 5)								
		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE							
12	INSTRU	INSTRUCTIONS)							
	PERCE	NT OF	CLASS REPRESENTED BY AMOUNT IN ROW (11)						
13	0.1% (se	ee Item 5							
1.4	ТҮРЕ С)F REP	ORTING PERSON (SEE INSTRUCTIONS)						
14	00								

	NAMES OF REPORTING PERSONS							
1	Viking I	Long Fun	nd Master Ltd.					
	CHECH	K THE A	APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗆				
2								
	SEC US	SE ONLY	Y					
3								
_	SOURC	CE OF F	UNDS (SEE INSTRUCTIONS)					
4	OO - otl	ner						
_	CHECH	K BOX I	F DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)					
5								
	CITIZE	ENSHIP	OR PLACE OF ORGANIZATION					
6	Cayman	Islands						
	1	_	SOLE VOTING POWER					
		7	0 (see Item 5)					
			SHARED VOTING POWER					
NUMBER OF S BENEFICIA	LLY	8	251,204 (see Item 5)					
OWNED BY I REPORTING P	G PERSON	PERSON	0	SOLE DISPOSITIVE POWER				
WITH		9	0 (see Item 5)					
			SHARED DISPOSITIVE POWER					
		10	251,204 (see Item 5)					
44	AGGRI	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON						
11	251,204	(see Iten	n 5)					
		K BOX I	F THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE					
12	INSTR	UCTION						
13			CLASS REPRESENTED BY AMOUNT IN ROW (11)					
13	0.1% (se	ee Item 5						
1.4	TYPE (OF REPO	ORTING PERSON (SEE INSTRUCTIONS)					
14	СО							

	NAMES OF REPORTING PERSONS								
1	Viking (Viking Global Opportunities Parent GP LLC							
	CHECH	K THE A	APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗆					
2									
	SEC US	SE ONLY	Y						
3									
4	SOURC	CE OF F	UNDS (SEE INSTRUCTIONS)						
4	OO - otl	ner							
_	CHECH	K BOX I	F DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)						
5									
	CITIZE	ENSHIP	OR PLACE OF ORGANIZATION						
6	Delawai	re							
			SOLE VOTING POWER						
		7	0 (see Item 5)						
			SHARED VOTING POWER						
NUMBER OF S BENEFICIA OWNED BY	LLY	8	24,238,620 (see Item 5)						
REPORTING F	PERSON	9	SOLE DISPOSITIVE POWER						
WITH		WIIH			WITH		0 (see Item 5)		
		10	SHARED DISPOSITIVE POWER						
		10	24,238,620 (see Item 5)						
44	AGGRI	EGATE .	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON						
11	24,238,6	620 (see]	Item 5)						
		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)							
12	INSTR	UCTION							
	DEDGE	NT OF	OLACC DEBDECENTED BY AMOUNT IN DOW (41)						
13			CLASS REPRESENTED BY AMOUNT IN ROW (11)						
		(see Item							
14		TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)							
17	00								

4	NAMES OF REPORTING PERSONS							
1	Viking (Viking Global Opportunities GP LLC						
	CHECK	THE A	APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) [
2		(b) l						
	SEC US	SE ONLY	Y					
3								
4	SOURC	E OF F	UNDS (SEE INSTRUCTIONS)					
4	OO - oth	ner						
	CHECK	K BOX I	F DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)					
5								
	CITIZE	NSHIP	OR PLACE OF ORGANIZATION					
6	Delawar	re						
	I		SOLE VOTING POWER					
		7	0 (see Item 5)					
			SHARED VOTING POWER					
NUMBER OF S BENEFICIA	LLY	8	24,238,620 (see Item 5)					
OWNED BY I	PERSON	0	SOLE DISPOSITIVE POWER					
WITH		9	0 (see Item 5)					
			10	SHARED DISPOSITIVE POWER				
		10	24,238,620 (see Item 5)					
44	AGGRI	EGATE .	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON					
11	24,238,6	520 (see]	Item 5)					
		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE						
12	INSTRUCTIONS)							
	PERCE	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)						
13		see Item						
14		TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)						
	00							

	NAMES OF REPORTING PERSONS						
1	Viking (Global O	pportunities Portfolio GP LLC				
	CHECI	K THE A	APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗆			
2				(b) ⊠			
	SEC US	SE ONLY	Y				
3							
4	SOURC	CE OF F	UNDS (SEE INSTRUCTIONS)				
4	OO - otl	ner					
_	CHECK	K BOX I	F DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)				
5							
	CITIZE	ENSHIP	OR PLACE OF ORGANIZATION				
6	Delawai	re					
			SOLE VOTING POWER				
	7 0 (see Item 5) SHARED VOTING POWER		0 (see Item 5)				
			SHARED VOTING POWER				
NUMBER OF S BENEFICIA	LLY	8	24,238,620 (see Item 5)				
REPORTING F	WNED BY EACH PORTING PERSON		PERSON	9	SOLE DISPOSITIVE POWER		
WITH		WITH		0 (see Item 5)			
		10	SHARED DISPOSITIVE POWER				
		10	24,238,620 (see Item 5)				
11	AGGRI	EGATE .	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
11	24,238,6	24,238,620 (see Item 5)					
		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE					
12	I (STR)	INSTRUCTIONS)					
	PERCE	NT OF	CLASS REPRESENTED BY AMOUNT IN ROW (11)				
13		see Item					
			ORTING PERSON (SEE INSTRUCTIONS)				
14		JI KEIV	ORTHO LEASON (SEE INSTRUCTIONS)				
1	00	00					

	311102		SCHEDOLL 135	1 450 10 01 10				
	NAMES	S OF RE	PORTING PERSONS					
1	Viking (Global Op	pportunities Illiquid Investments Sub-Master LP					
2	CHECH	HECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) □ (b) ⊠						
3	SEC US	SE ONLY	Y					
	SOURC	E OF F	UNDS (SEE INSTRUCTIONS)					
4	OO - otl	ner						
5	CHECH	K BOX I	F DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2	2(E)				
	CITIZE	ENSHIP	OR PLACE OF ORGANIZATION					
6	Cayman	Islands						
			SOLE VOTING POWER					
		7	0 (see Item 5)					
			SHARED VOTING POWER					
NUMBER OF S BENEFICIA	ALLY	8	24,238,620 (see Item 5)					
REPORTING I	PERSON	VNED BY EACH ORTING PERSON	0	SOLE DISPOSITIVE POWER				
WITH		9	0 (see Item 5)					
		10	SHARED DISPOSITIVE POWER					
		10	24,238,620 (see Item 5)					
11	AGGRI	EGATE A	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON					
11	24,238,6	520 (see I	Item 5)					
12		K BOX II UCTION	F THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE NS)					
	PERCE	NT OF	CLASS REPRESENTED BY AMOUNT IN ROW (11)					
13	12.9% (see Item	5)					
1.4	ТҮРЕ (OF REPO	ORTING PERSON (SEE INSTRUCTIONS)					
14	PN	PN						

				_					
	NAMES	NAMES OF REPORTING PERSONS							
1	O. Andr	eas Halv	orsen						
	CHECI	K THE A	APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗆					
2									
	SEC US	SE ONLY	v.						
3	SEC USE ONLY								
	GOVIDA	× 0 0 0							
4			UNDS (SEE INSTRUCTIONS)						
_	OO - otl	ner							
_	CHECH	K BOX I	F DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E	E) 🗆					
5									
	CITIZE	ENSHIP	OR PLACE OF ORGANIZATION						
6	Norway								
			SOLE VOTING POWER						
		7	0 (see Item 5)						
			SHARED VOTING POWER						
NUMBER OF S BENEFICIA	LLY	8	25,120,991 (see Item 5)						
OWNED BY REPORTING F	PERSON	9	SOLE DISPOSITIVE POWER						
WITH	WITH		WIIH		0 (see Item 5)				
			SHARED DISPOSITIVE POWER						
		10	25,120,991 (see Item 5)						
	AGGRI	EGATE .	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON						
11	25,120,9	991 (see l	Item 5)						
		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)							
12	INSTR	UCTION							
13			CLASS REPRESENTED BY AMOUNT IN ROW (11)						
10	13.4% (see Item	5)						
1 /	TYPE (OF REPO	ORTING PERSON (SEE INSTRUCTIONS)						
14	IN								

	NAMES	NAMES OF REPORTING PERSONS									
1	David C	. Ott									
	CHECH	THE A	APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗆							
2				(b) ⊠							
	SEC US	SE ONLY	Y								
3											
4	SOURC	E OF F	UNDS (SEE INSTRUCTIONS)								
4	OO - otl	ner									
_	CHECH	K BOX I	F DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)) 🗆							
5											
	CITIZE	ENSHIP	OR PLACE OF ORGANIZATION								
6	United S	States									
		_	SOLE VOTING POWER								
		7	0 (see Item 5)								
			SHARED VOTING POWER								
NUMBER OF S BENEFICIA	LLY	8	25,120,991 (see Item 5)								
OWNED BY I		PERSON	0	SOLE DISPOSITIVE POWER							
WITH		WITH		WITH				Н	Н	9	0 (see Item 5)
		10	SHARED DISPOSITIVE POWER								
		10	25,120,991 (see Item 5)								
44	AGGRI	EGATE .	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON								
11	25,120,9	991 (see l	Item 5)								
		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)									
12	INSTR	UCTION									
13			CLASS REPRESENTED BY AMOUNT IN ROW (11)								
	13.4% (see Item	5)								
1.4	TYPE (OF REPO	ORTING PERSON (SEE INSTRUCTIONS)								
14	IN										

	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		3 61122 622 132	1 450 10 01 10	
	NAMES	S OF RE	CPORTING PERSONS		
1	Rose S. Shabet				
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP			(a) □ (b) ⊠	
3	SEC USE ONLY				
4	SOURCE OF FUNDS (SEE INSTRUCTIONS)				
	OO - other				
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)				
6	CITIZENSHIP OR PLACE OF ORGANIZATION				
	United States				
		7	SOLE VOTING POWER		
			0 (see Item 5)		
		8	SHARED VOTING POWER		
NUMBER OF S BENEFICIA	LLY		25,120,991 (see Item 5)		
OWNED BY REPORTING I	PERSON	9	SOLE DISPOSITIVE POWER		
WITH			0 (see Item 5)		
		10	SHARED DISPOSITIVE POWER		
		10	25,120,991 (see Item 5)		
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	25,120,991 (see Item 5)				
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)				
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)				
	13.4% (see Item 5)				
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)				
	IN				

EXPLANATORY NOTE

Pursuant to Rule 13d-2 of the Securities Exchange Act of 1934, as amended, this Amendment No. 3 to the Schedule 13D ("Amendment No. 3") amends certain items of the Schedule 13D filed with the Commission on July 8, 2019, as amended and supplemented by Amendment No. 1 filed with the Commission on July 19, 2023 and Amendment No. 2 filed with the Commission on November 22, 2023 (collectively, the "Schedule 13D") relating to the Common Stock, par value \$0.001 per share (the "Common Stock") of BridgeBio Pharma, Inc., a Delaware corporation (the "Issuer"). All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D.

Item 4. Purpose of Transaction

Item 4 of the Schedule 13D is hereby amended and supplemented as follows:

On August 16, 2024, the Issuer, on the recommendation of a special committee of independent and disinterested directors of the Issuer, entered into a transaction agreement (the "<u>Transaction Agreement</u>") providing for the formation and funding by certain third party investors (the "<u>Investors</u>") of GondolaBio, LLC, a Delaware limited liability company ("<u>GondolaBio</u>"), as a joint venture for the purpose of researching, developing, manufacturing and commercializing pharmaceutical products, including those contributed to GondolaBio by the Issuer (the "<u>Transaction</u>"). The Investors providing financing to GondolaBio consist of an investor syndicate, including Opportunities Fund and Viking Global Opportunities Drawdown (Aggregator) LP ("<u>VGOD</u>"). The general partner of VGOD is Viking Global Opportunities Drawdown Portfolio GP LLC, whose sole member is Viking Global Opportunities Drawdown GP LLC, whose sole member is Opportunities Parent. The Transaction was consummated (the "<u>Closing</u>") on the date of signing the Transaction Agreement.

Pursuant to the Transaction Agreement, the Issuer contributed to GondolaBio certain early-stage clinical and pre-clinical stage programs in the areas of Erythropoietic Protoporphyria, Alpha-1 Antitrypsin Deficiency, and Tuberous Sclerosis Complex. The Investors have committed \$300 million of tranched financing to GondolaBio. The initial interest in GondolaBio of each of Opportunities Fund and VGOD is approximately 12% and 6%, respectively, and is expected to increase as additional tranches of capital contributions are funded.

Also on August 16, 2024, each of the Investors, including Opportunities Fund and VGOD, became a party to the Amended and Restated Limited Liability Company Agreement of GondolaBio (the "<u>LLC Agreement</u>"). The LLC Agreement sets forth, among other things, the economic and governance rights of the members of GondolaBio, including governance rights, economic preferences, privileges, restrictions and obligations of the members.

The foregoing descriptions of the Transaction Agreement and the LLC Agreement do not purport to be complete and are qualified in their entirety by reference to the full text thereof, copies of which are filed as Exhibit 99.4 and Exhibit 99.5, respectively, to this Amendment No. 3 and are incorporated herein by reference.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

Item 6 of the Schedule 13D is hereby amended and supplemented as follows:

The information set forth or included in Item 4 of this Amendment No. 3 is incorporated herein by reference.

Item 7. Materials to be Filed as Exhibits

Item 7 of the Schedule 13D is hereby amended and supplemented as follows:

Exhibit No.	Description	
99.4	Transaction Agreement, dated as of August 16, 2024, by and among the Issuer, the Investors and GondolaBio (incorporated by reference to Exhibit 10.1 to the Issuer's current report on Form 8-K dated August 20, 2024).	
99.5	Amended and Restated Limited Liability Company Agreement of GondolaBio, dated as of August 16, 2024 (incorporated by reference Exhibit 10.2 to the Issuer's current report on Form 8-K dated August 20, 2024).	

SIGNATURES

After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated: August 20, 2024

By: /s/ Scott M. Hendler

Name: Scott M. Hendler on behalf of O. Andreas Halvorsen (1)

By: /s/ Scott M. Hendler

Name: Scott M. Hendler on behalf of David C. Ott (2)

By: /s/ Scott M. Hendler

Name: Scott M. Hendler on behalf of Rose S. Shabet (3)

- (1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737).
- (2) Scott M. Hendler is signing on behalf of David C. Ott, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Ott on February 12, 2021 (SEC File No. 005-49737).
- (3) Scott M. Hendler is signing on behalf of Rose S. Shabet, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Ms. Shabet on February 12, 2021 (SEC File No. 005-49737).